Romark Completes Enrollment in Phase II Hepatitis Combination Therapy Study
Posted on: Wednesday, 21 May 2008, 12:00 CDT
Romark Laboratories has announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in US patients with chronic hepatitis C genotype 1 who have previously failed to respond to the standard of care therapy.
The study, called Stealth C-2, is the second in a series of clinical trials designed to evaluate the safety and efficacy of nitazoxanide tablets in combination with Pegasys (peginterferon alfa-2a) or peginterferon and Copegus (ribavirin) in patients with chronic hepatitis C. STEALTH C-2 is a randomized, double-blind, placebo-controlled trial conducted in the US in 60 patients with chronic hepatitis C genotype 1, who are non-responders to prior peginterferon and ribavirin therapy.
The study is designed to evaluate the effectiveness and safety of nitazoxanide administered 500mg twice daily for four weeks followed by nitazoxanide plus Pegasys plus Copegus combination therapy for 48 weeks, compared to placebo for four weeks followed by placebo plus Pegasys plus Copegus combination therapy for 48 weeks. Pegasys and Copegus are being provided under a collaborative agreement between Romark and Hoffmann-La Roche.
Marc Ayers, CEO of Romark, said: "We believe nitazoxanide represents a promising approach to the treatment of hepatitis C for the millions of people who are infected with this serious liver disease."
Source: Datamonitor
Related Articles
- Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
- Pharmasset Announces Initiation of Hepatitis Antiviral Combination Study
- Pharmasset Reports Preliminary Results of a 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
- Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
- Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-Week Combination Study for the Treatment of Chronic Hepatitis C
- Roche's Investigational Polymerase Inhibitor, Combined With PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
- Pharmasset Commences Dosing in 28-Day Combination Study of R7128 With Pegasys(R) Plus Copegus(R) for Hepatitis C
- New Data on Most-Prescribed Hepatitis C Therapy PEGASYS(R) to Be Presented at Digestive Disease Week
- New Studies With Pegasys(R) Plus Copegus(R) in Hepatitis C Treatment to Be Presented at AASLD Annual Meeting
- Roche Announces New Study to Evaluate Pegasys and Copegus to Treat Hepatitis C in Liver Transplant Patients
 |
 |
User Comments (0)
RSS Feeds